Ironwood Provides Second Quarter 2015 Investor Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its second quarter 2015 and recent business activities.
“Ironwood made substantial progress in the second quarter of 2015, with continued strong performance for each of our key value drivers – LINZESS, our innovative pipeline and our strong commercial capabilities,” said Peter Hecht, chief executive officer of Ironwood. “LINZESS is the branded market leader in its category, with continued double-digit prescription growth and brand profitability in the U.S. We reported multiple positive data readouts from our pipeline including Phase I data from IW-1973, which provides the first evidence of the potential for our sGC stimulators platform to deliver blockbuster products targeting severe cardiovascular and fibrotic diseases with large unmet needs.
Help employers find you! Check out all the jobs and post your resume.
“Ironwood made substantial progress in the second quarter of 2015, with continued strong performance for each of our key value drivers – LINZESS, our innovative pipeline and our strong commercial capabilities,” said Peter Hecht, chief executive officer of Ironwood. “LINZESS is the branded market leader in its category, with continued double-digit prescription growth and brand profitability in the U.S. We reported multiple positive data readouts from our pipeline including Phase I data from IW-1973, which provides the first evidence of the potential for our sGC stimulators platform to deliver blockbuster products targeting severe cardiovascular and fibrotic diseases with large unmet needs.
Help employers find you! Check out all the jobs and post your resume.